EGFR (K716A/T790M/C797S/L858R)
Sign in to save this workspaceEGFR · Variant type: compound · HGVS: p.K716A;p.T790M;p.C797S;p.L858R
Components
p.K716Ap.T790Mp.C797Sp.L858R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Gilteritinib | 95.6% | 4.4% | 88.97 |
| 2 | Pacritinib | 95.1% | 4.9% | 88.64 |
| 3 | Lazertinib | 87.8% | 12.2% | 97.47 |
| 4 | Neratinib | 76.4% | 23.6% | 93.18 |
| 5 | Mobocertinib | 73.0% | 27.0% | 97.22 |
| 6 | Canertinib | 68.5% | 31.5% | 96.49 |
| 7 | Vandetanib | 66.3% | 33.7% | 95.74 |
| 8 | Erlotinib | 61.1% | 38.9% | 99.75 |
| 9 | Abemaciclib | 58.1% | 41.9% | 91.48 |
| 10 | Deucravacitinib | 57.9% | 42.1% | 98.99 |
| 11 | Entrectinib | 54.3% | 45.7% | 93.69 |
| 12 | Repotrectinib | 49.8% | 50.2% | 84.21 |
| 13 | Fedratinib | 48.3% | 51.7% | 96.21 |
| 14 | Defactinib | 41.8% | 58.2% | 92.68 |
| 15 | Avapritinib | 35.0% | 65.0% | 97.73 |
| 16 | Pralsetinib | 31.5% | 68.5% | 93.43 |
| 17 | Pirtobrutinib | 28.3% | 71.7% | 99.49 |
| 18 | Sunitinib | 28.2% | 71.8% | 91.73 |
| 19 | Tivozanib | 27.2% | 72.8% | 92.42 |
| 20 | Selpercatinib | 21.7% | 78.3% | 96.72 |
| 21 | Palbociclib | 16.2% | 83.8% | 98.75 |
| 22 | Abrocitinib | 12.1% | 87.9% | 99.50 |
| 23 | Darovasertib | 11.7% | 88.3% | 96.99 |
| 24 | Mitapivat | 11.1% | 88.9% | 100.00 |
| 25 | Rabusertib | 8.7% | 91.3% | 98.74 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Gilteritinib | 95.6% | 91.0% | +4.6% |
| Pacritinib | 95.1% | — | — |
| Lazertinib | 87.8% | 100.0% | -12.2% |
| Neratinib | 76.4% | 100.0% | -23.6% |
| Mobocertinib | 73.0% | 100.0% | -27.0% |
| Canertinib | 68.5% | 98.4% | -29.9% |
| Vandetanib | 66.3% | 99.3% | -33.0% |
| Erlotinib | 61.1% | 99.4% | -38.4% |
| Abemaciclib | 58.1% | — | — |
| Deucravacitinib | 57.9% | — | — |
| Entrectinib | 54.3% | — | — |
| Repotrectinib | 49.8% | — | — |
| Fedratinib | 48.3% | — | — |
| Defactinib | 41.8% | 94.6% | -52.8% |
| Avapritinib | 35.0% | — | — |
| Pralsetinib | 31.5% | 99.1% | -67.6% |
| Pirtobrutinib | 28.3% | — | — |
| Sunitinib | 28.2% | — | — |
| Tivozanib | 27.2% | — | — |
| Selpercatinib | 21.7% | — | — |
| Palbociclib | 16.2% | — | — |
| Abrocitinib | 12.1% | — | — |
| Darovasertib | 11.7% | — | — |
| Mitapivat | 11.1% | — | — |
| Rabusertib | 8.7% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.4ms